BioSpace News Archive

Awards for achievement in the contact lens field were presented recently to three team members of Innovega, a company engaged in developing stylish, lightweight, wearable display technology with a panoramic field of view for virtual and augmented reality

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17, 2020 at 4:00 PM ET . The c

- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter of calendar year 2020 - 87.7% one-year response rate in LIBERTY open-label extension study supports submission of NDA for relugolix combination tablet for women with heavy menstrual bleeding associated with uterine fibroids in April 2020 - Enrollment completed in Phase 3 SPIRIT 2 and SPIRIT 1 studies in women w

Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Animal Health Summit on Monday, Feb. 24, 2020, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:40 a.m. ET.

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that Dragan Cicic, MD, has joined the Company as Senior Vice President, Clinical Development. Dr. Cicic will oversee the Company’s clinical development activities. He will report directly to Angelos Stergiou, MD,

EDMONTON, Alberta, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will present at NobleCon16 - Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17, 2020 at 3:30 p.m. ET in Holly

Palo Alto, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Cognoa , the leading digital therapeutics company focused on pediatric behavioral health, announced today that three company executives will be on stage at the third annual DTx West 2020 , taking place in San Mateo, California, February 18 to 20. All events take place on the first day of the conference, Tuesday, February 18. Details are as follows: At 10:15 a.m., Brent Vaughan, Co-founder and CEO of Cognoa will moderate a panel di

SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its acquiree Sapphire Biotech, Inc. (“Sapphire”) has signed a Sponsored Research Agreement (“SRA”) with Arizona State University (“ASU”) to conduct preclinical studies using Quiescin Sulfhydryl Oxidase 1 (“QSOX1”) inhibitors as anti-neoplasti

“We can look back on a very strong quarter in which Group sales grew by a significant 22 percent adjusted for currency, driven in particular by Integrated Solutions, whose sales adjusted for currency rose by a remarkable 45 percent.

MIRAMAR, Fla., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday February 13, 2020 at 11:00 AM Eastern time. Agenda 2019-nCOV coronavirus initiatives 5/2 dividends in Generex and NuGenerex Immuno-Oncology ALTuCELL Closing S1 funding update Nasdaq listing update